All articles tagged with #pcsk9
Merck has developed a new pill called enlicitide that significantly reduces LDL cholesterol levels by blocking the PCSK9 protein, showing promising results in clinical trials with a 20% reduction in heart attack and stroke rates among high-risk patients, and offering a potentially more affordable alternative to existing injectable treatments.
Researchers have developed a new therapy using polypurine hairpins to inhibit PCSK9, significantly reducing LDL cholesterol levels by nearly 50% without the side effects associated with statins, offering a promising alternative for managing hypercholesterolemia and preventing atherosclerosis.
A new genetic therapy using polypurine hairpins to inhibit PCSK9 significantly reduces cholesterol levels by nearly 50%, offering a promising alternative to traditional statins and potentially reducing cardiovascular disease risk.
A patent case before the US Supreme Court over rights to therapeutic antibodies that are used to treat high cholesterol could have far-reaching impacts on drug prices and technology. The decision could affect how specific patents of any ilk must be when they describe an invention, and how broad they can be. A win by Amgen could hinder the development of new medicines by restricting competition and discouraging the development of multiple therapeutic antibodies that bind to the same target.